This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

[video] New Tablet From Boston Therapeutics Reduces Sugar Intake for Diabetics

The video this transcript is based on appeared on December 19.

NEW YORK ( TheStreet) -- Boston Therapeutics new PAZ320 tablet is designed to reduce a person's sugar intake before eating a meal.


Debra Borchardt:
Diabetes is a disease that is affecting millions and millions of Americans but there are some companies that are addressing the problems here and taking kind of a novel approach. One of those is Boston Therapeutics (BTHE) and I'm going to talk to the CEO Dr. David Platt. He has a couple of products and one is PAZ320 and it's a tablet that you take before you eat that reduces the amount of sugar your body absorbs and then another is Ipoxyn and it helps with problems such as foot ulcers. Dr. Platt, let's talk about the first one, the PAZ320. Everything we eat has sugar in it, just everything, so this tablet sounds like it's really gonna help that.

Dr. David Platt:
Absolutely, what we use is called a non-systemic approach. The other drugs, other diabetes drugs, are systemic, goes into the blood and operate only or activate mechanism in the body in the blood. What we do, we have a chemistry that blocks the enzyme in the intestine and as a consequence the sugar in the food is less digested. In our clinical trial we show forty percent reduction of the amount of sugar that goes into the blood. We actually don't reduce the sugar in the blood, we don't let it go up. And the sugar that is not digested by the enzyme goes out to the system.

Debra Borchardt:
Right, and if you've ever tried to eat less sugar you know it is almost impossible. Everything on the shelves has tons and tons of sugar in it. Another issue with diabetic patients, if you have friends or family with diabetes you know that these wounds, these problems that come as a result the disease. This drug Ipoxyn helps the healing in those wounds, right?

Dr. David Platt:
Ipoxyn is basically an anti-necrosis drug and it treats hypoxia or condition of lack of oxygen in the tissue. So [the] wound is usually started by a lack of oxygen. So it's an IV carbohydrate carry oxygenated, injected IV. It goes into the body, picks up an oxygen molecule in releasing next to the wound to treat the hypoxia condition called oxygen therapeutics.

Debra Borchardt:
Alright well these are two very fascinating new products. Now the PAZ320 is being tested now for use with other diabetes drugs but hopefully in the future it will get approved for all of us that want to reduce the amount of sugar in and have tried but but have a hard time doing so, not for diet, just truly for reducing the sugar that is absorbed in your body. That's doctor David Platt, his company is Boston Therapeutics, they're fairly new company traded over-the-counter, and I'm Debra Borchardt with TheStreet.

Written by Debra Borchardt in New York.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.18 -0.10%
FB $103.27 2.20%
GOOG $683.11 -0.15%
TSLA $154.76 7.70%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs